All In Biotech

Drug Trial Radar · NCT06812780

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389

A Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389 (CAMPOLINA)

Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Feb 4, 2025

Primary completion

Sep 4, 2025

Study completion Sep 4, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.

Conditions

  • Hepatic Impairment

Interventions

  • AZD2389Drug

    Single oral dose of AZD2389 in participants from all cohorts

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma PK parameter CmaxTime frame: pre-dose to 48 hours post-dose
  2. Plasma PK parameter AUCinfTime frame: pre-dose to 48 hours post-dose
  3. Plasma PK parameter AUClastTime frame: pre-dose to 48 hours post-dose

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Chandler, Arizona

  • Research Site

    Rialto, California

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.